September 23, 2019 / Waltham, MA – Nocion Therapeutics today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“We are thrilled to be recognized as a Fierce 15 company, an honor that reflects both the novelty and scope of our platform and the dedication of our entire team,” said Dr. Richard Batycky, CEO of Nocion. “Our unique platform is generating therapeutics targeting neurons to mediate cough, itch, pain and inflammation but without the addictive properties of opioids or other off-target effects.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 17th annual Fierce 15 selection.
“This year has seen unrivalled scientific talent in the early-stage life sciences world and it has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” said Ben Adams, Senior Editor of FierceBiotech. “Each company brought something different, exciting and potentially life-changing for myriad patients around the world across a host of diseases and disorders, using cutting-edge science, top-notch teams and a drive to genuinely make the world a better place, despite the risks and challenges that, as ever in biotech, lay ahead.”
About Nocion Therapeutics
Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons. For more information, visit: www.nociontx.com.
About FierceBiotech
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
